A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials
- 1 June 2010
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 66 (2), 523-531
- https://doi.org/10.1111/j.1541-0420.2009.01303.x
Abstract
Summary A surrogate marker (S) is a variable that can be measured earlier and often more easily than the true endpoint (T) in a clinical trial. Most previous research has been devoted to developing surrogacy measures to quantify how well S can replace T or examining the use of S in predicting the effect of a treatment (Z). However, the research often requires one to fit models for the distribution of T given S and Z. It is well known that such models do not have causal interpretations because the models condition on a postrandomization variable S. In this article, we directly model the relationship among T, S, and Z using a potential outcomes framework introduced by Frangakis and Rubin (2002, Biometrics 58, 21–29). We propose a Bayesian estimation method to evaluate the causal probabilities associated with the cross‐classification of the potential outcomes of S and T when S and T are both binary. We use a log‐linear model to directly model the association between the potential outcomes of S and T through the odds ratios. The quantities derived from this approach always have causal interpretations. However, this causal model is not identifiable from the data without additional assumptions. To reduce the nonidentifiability problem and increase the precision of statistical inferences, we assume monotonicity and incorporate prior belief that is plausible in the surrogate context by using prior distributions. We also explore the relationship among the surrogacy measures based on traditional models and this counterfactual model. The method is applied to the data from a glaucoma treatment study.Keywords
This publication has 32 references indexed in Scilit:
- Mediation analysis with principal stratificationStatistics in Medicine, 2009
- Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study: The Impact of Treatment and Other Baseline FactorsOphthalmology, 2009
- Evaluating Candidate Principal Surrogate EndpointsBiometrics, 2008
- Criteria for Surrogate End PointsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2007
- On Model Expansion, Model Contraction, Identifiability and Prior Information: Two Illustrative Scenarios Involving Mismeasured VariablesStatistical Science, 2005
- Latent Class Model DiagnosisBiometrics, 2000
- Identifiability, Improper Priors, and Gibbs Sampling for Generalized Linear ModelsJournal of the American Statistical Association, 1999
- Identifiability, Improper Priors, and Gibbs Sampling for Generalized Linear ModelsJournal of the American Statistical Association, 1999
- Bounds on Treatment Effects from Studies with Imperfect ComplianceJournal of the American Statistical Association, 1997
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992